Health alliance to put Midlands at centre of UK’s clinical research

The Midlands Health Alliance (MHA) has been developed to showcase what the English region has to offer with its cutting-edge health research – and is inviting industry partners to invest in the region.

The collaboration is a partnership between Midlands-based NIHR-funded infrastructure – NIHR Biomedical Research Centres (BRCs), Clinical Research Facilities (CRFs), Applied Research Collaborations (ARCs), and Clinical Research Networks (CRNs) – and the Academic Health Science Networks (AHSNs) in the Midlands, and will be led by the directors of the NIHR BRCs in Nottingham and Leicester.

The increased research and collaboration, conducted by internationally recognised experts working together, sharing skills and expertise, will improve healthcare for patients across the Midlands and beyond.

The MHA will work together with other regional organisations to ensure strategic and research alignment and to maximise inward investment to the region.

This includes the Midlands Health Innovation (MHI), a partnership that coordinates the collective excellence in Life Sciences of seven universities across the Midlands in a bid to deliver improved health and regional growth.

“Our vision is to drive clinical research that meets some of the ‘grand challenges’ of modern medicine, putting the Midlands at the heart of UK biomedical research excellence,” said MHA’s Operational Manager Lois Daniels.

“We’ve developed a single business process to make it easier and quicker for industry to work with the leading expert investigators within the NHS to harness the exciting and wide-ranging opportunities in this area.”

A map showing the industry companies the region has worked with has been developed to show the quantity of research taking place in the Midlands and the variety of expertise the region has to offer.

The MHA is co-chaired by Professor Melanie Davies CBE, from the University of Leicester and Director of the NIHR Leicester BRC, Professor David Adams, Pro-Vice-Chancellor, Dean of Medicine and Head of the University of Birmingham’s College of Medical and Dental Sciences and Professor Ian Hall, Director of the NIHR Nottingham BRC.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...